New program aims to make HIV injections easier for women facing homelessness or food insecurity
NCT ID NCT06411223
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 38 times
Summary
This study tests a pharmacist-led program to help women with HIV who also face social challenges like housing or food insecurity. The program supports switching from daily pills to a long-acting injectable medication (cabotegravir/rilpivirine) given every two months. The goal is to see if this approach is practical and acceptable for these women.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yale Clinical and Community Research
New Haven, Connecticut, 06519, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cabotegravir/Rilpivirine (long-acting injectable HIV medication)
What this could lead to
If successful, this could show that a pharmacist-led support program helps women with social challenges stick with long-acting HIV treatment, improving their health.
What could go wrong
This is a small early-phase study (50 people) focused on feasibility, not on proving the treatment works. Results may not apply to all women or settings.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.